Showing 3431-3440 of 8741 results for "".
- One to Watch: Nektar Therapeutics' Rezpegaldesleukin Shows Promise in Phase 1b AD Studyhttps://practicaldermatology.com/news/one-to-watch-nektar-therapeutics-rezpegaldesleukin-shows-promise-in-phase-1b-ad-study/2462000/Nektar Therapeutics’ rezpegaldesleukin met several clinical efficacy endpoints with statistically significance, including Body Surface Area (BSA), Dermatology Life (DLQI), and Patient-Oriented Eczema Measure (POEM) in addition to reported efficacy for Eczema Area and Severity
- Innovation in Action: A Newly Developed Anti-bacterial Silver Gel May Best Other Silver-based Drugshttps://practicaldermatology.com/news/innovation-in-action-a-newly-developed-anti-bacterial-silver-gel-may-best-other-silver-based-drugs/2461999/A new anti-bacterial gel based on silver and sulfur-containing amino acids may be one hundred times more effective than other silver-based antibacterials, according to research in the Journal of Material
- New Surgical Technique Offers Hope to Folliculitis Decalvans Patientshttps://practicaldermatology.com/news/experimental-surgical-technique-offers-hope-to-folliculitis-decalvans-patients/2461997/The lack of long-term solutions in the challenging treatment of folliculitis decalvans (FD) led Sanusi Umar MD, and colleagues from Dr. U Hair and Skin Clinic to develop and patent a novel device that holds potential for sustained FD remission.
- Cetaphil Takes on Aging Skin with New Skincare Linehttps://practicaldermatology.com/news/cetaphil-takes-on-aging-skin-with-new-skincare-line/2461995/Galderma is rolling out Cetaphil Healthy Renew, its first-ever healthy aging skincare line. "Aging skin is a particular point of frustration for my sensitive skin patients due to increased risks of irritation and an already compromised skin barrier,” says Cetaphil partn
- Biosimilar News: Samsung Bioepis, Sandoz to Develop SB17, a Proposed Stelara Biosimilar to Stelarahttps://practicaldermatology.com/news/biosimilar-news-samsung-bioepis-sandoz-to-develop-sb17-a-proposed-stelara-biosimilar-to-stelara/2461991/Samsung Bioepis Co., Ltd. has entered into a commercialization agreement with Sandoz for SB17, a proposed biosimilar to Stelara (ustekinumab). Samsung Bioepis will be responsible for development, regulatory registration and manufacture and supply of the product in t
- Regenerative Medicine in Action: Scarless Wound Recovery May Be Possible with New Autologous Blood Techniquehttps://practicaldermatology.com/news/regenerative-medicine-in-action-scarless-wound-recovery-may-be-possible-with-new-autologous-blood-technique/2461982/A new technology that utilizes autologous blood to produce three-dimensional microvascular implants may help make scarless wound recovery a reality. Led by Professor Joo H. Kang from the Department of Biomedical Engineering at UNIST, the team developed a microfluidic system capable
- Dan Walker Named VP of US Commercial Operations at SciBasehttps://practicaldermatology.com/news/dan-walker-named-vp-of-us-commercial-operations-at-scibase/2461977/Dan Walker is SciBase’s new VP of US Commercial Operations. SciBase's products include Nevisense and Nevisense Go which address melanoma detection, non-melanoma skin cancer detection, and skin barrier assessment. Mr. Walker was previously Senior Dire
- Houston Dermatologist Rolls Out New Class of Topical Pain Relievershttps://practicaldermatology.com/news/houston-dermatologist-rolls-out-new-class-of-topical-pain-relievers/2461974/Milton D. Moore, MD, a dermatologist and founder & CEO of Moore Unique Skin Care, LLC and
- Kenvue Launches Two New Tylenol Precise Pain-relieving Creamshttps://practicaldermatology.com/news/kenvue-launches-two-new-tylenol-precise-pain-relieving-creams/2461973/Kenvue Inc. is rolling out two new topical pain-relieving creams: Tylenol Precise Pain Relieving Cream and Tylenol Precise Cooling Pain Relieving Cream. These are among the first U.S. product launches from Kenvue since it became a publicly traded
- New CEO for SciBasehttps://practicaldermatology.com/news/new-ceo-for-scibase/2461967/Pia Renaudin is SciBase’s new Chief Executive Officer (CEO), effective October 1st, 2023. SciBase's products include Nevisense and Nevisense Go and address melanoma detection, non-melanoma skin cancer detection and skin barrier assessment. Ms.